TrialBMC dermatology2006
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
Kim A Papp et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it